Geographic atrophy grew at a statistically significantly slower rate after treatment with APL-2, a complement C3 inhibitor from Apellis Pharmaceuticals, than with placebo, according to preliminary 18-month data from the phase 2 FILLY trial presented at the Macula Society meeting.
“The findings from the FILLY study further implicate the complement pathway in the pathogenesis of advanced forms of AMD like GA. APL-2 is unique because it acts on C3, which is the convergence of the complement pathways. Future work in phase 3 will determine what effect decreasing complement will have (Read more...)
Uncategorized